B2M and cancer: Building on the safety of vector-engineered CAR T cells in clinical applications for HIV and cancer (34–36), dual-targeting miRNAs against CD3ζ to abrogate TCR expression, and a single miRNA against β2M for tuned MHC-I silencing were selected and incorporated into a bimodal lentiviral construct also coding the M5CAR gene.